CStone Pharmaceuticals
Kai Wang has a diverse work experience spanning over various roles and companies. Kai started their career as an Emergency Physician at Shanghai emergency medical center in 2006. In 2008, they joined Zhongtai Pharmaceutical Industry as a Medical Sales Representative specializing in GI Oncology and Hematology until 2012.
Kai then transitioned into the field of pharmaceutical marketing, working as an Associate Product Manager at Sanofi Genzyme from 2012 to 2013, focusing on the commercialization of Cerezyme in China and pre-launch readiness for orphan drugs in the Genzyme pipeline.
Kai continued their marketing career at Hisun Pfizer Pharmaceuticals Co., LTD. from 2013 to 2014, serving as a Product Manager for Breast cancer.
From 2014 to 2016, Kai worked at AstraZeneca as a Product Manager, responsible for the brand ownership and launch lead for Carprelsa for thyroid cancer, as well as indication ownership of IRESSA in the respiratory department.
In 2016, they joined Sanofi as a Senior Brand Manager before being promoted to Marketing Manager in 2017. Kai later became an Associate Marketing Director in 2020 and then took on the role of Solid Tumor Marketing Head in 2021.
Most recently, Kai Wang is the Marketing Director at Genzyme, starting in 2021.
Kai Wang earned a Medical Bachelor's degree in Clinical Medicine from Tongji University, completing their studies from 2001 to 2006.
This person is not in any offices
CStone Pharmaceuticals
CStone is a biopharmaceutical company focused on developing and commercializing innovative immuno-oncology and precision medicines to address the unmet medical needs of cancer patients in China and worldwide. Established at the end of 2015, CStone has assembled a world-class management team with extensive experience in innovative drug development, clinical research, and commercialization. With a strategic emphasis on immuno-oncology combination therapies, the Company has built an oncology-focused pipeline of 16 drug candidates, including 5 late-stage candidates at pivotal trials or registration stages. With an experienced team, a rich pipeline, a robust clinical development-driven business model and substantial funding, CStone’s vision is to become a world-renowned biopharmaceutical company that is leading the way to conquering cancer.